Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.

Autor: Liao JB; University of Washington School of Medicine, Seattle, Washington, USA johnliao@uw.edu., Gwin WR; University of Washington School of Medicine, Seattle, Washington, USA., Urban RR; University of Washington School of Medicine, Seattle, Washington, USA., Hitchcock-Bernhardt KM; University of Washington School of Medicine, Seattle, Washington, USA., Coveler AL; University of Washington School of Medicine, Seattle, Washington, USA., Higgins DM; University of Washington School of Medicine, Seattle, Washington, USA., Childs JS; University of Washington School of Medicine, Seattle, Washington, USA., Shakalia HN; University of Washington School of Medicine, Seattle, Washington, USA., Swensen RE; Valley Medical Center, Renton, Washington, USA., Stanton SE; Providence Cancer Center, Portland, Oregon, USA., Tinker AV; BC Cancer Agency, Vancouver, British Columbia, Canada., Wahl TA; Swedish Medical Center, Seattle, Washington, USA., Ancheta RG; Kaiser Permanente, Seattle, Washington, USA., McGonigle KF; University of Washington School of Medicine, Seattle, Washington, USA., Dai JY; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Disis ML; University of Washington School of Medicine, Seattle, Washington, USA., Goff BA; University of Washington School of Medicine, Seattle, Washington, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Sep; Vol. 9 (9).